 |
Kristin E. Mondy, M.D.
|
|
Kristin E. Mondy, M.D. Assistant Professor of Medicine Office Location: Washington University School of Medicine Dr. Mondy received her Sc.B. from Brown University and her M.D. from the University of Texas Southwestern. She completed her Internal Medicine residency and Infectious Diseases fellowship at Barnes-Jewish Hospital and Washington University School of Medicine. She was in private practice in St. Louis for nearly two years and recently joined the Infectious Diseases faculty of Washington University in July 2004. She is currently an Instructor in Medicine at both Washington University and the John Cochran VAMC. Research Interests My primary research interests are in the area of HIV-related metabolic complications. I have ongoing research in complications related to antiretroviral therapies including lipodystrophy, insulin resistance, and bone metabolic complications. I am also involved in other HIV-related studies at the Washington University Aids Clinical Trials Unit including a study of the natural history of HIV disease with antiretroviral therapy and other metabolic studies. Non-HIV interests include the epidemiology and treatment of resistant pathogens such as VRE and resistant Candida. Publications 1. Mondy KE, Shannon W, Mundy LM. Zinc bacitracin capsules vs. placebo for enteric eradication of vancomycin-resistant enterococcus faecium. Clinical Infectious Diseases 2001;33:473-6. 2. Mondy K, Tebas P. Bone abnormalities in HIV-infected patients on HAART. AIDS Reviews 2001;3:82-88. 3. Yarasheski KE, Breda E, Hoffmann M, Claxton S, Schulte JN, Mondy K, Tebas P, Cobelli C, Powderly WG. Both insulin resistance and relative _-cell insensitivity are characteristics of HIV-associated glucose intolerance. 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Athens, Greece. Antiviral Ther 2001; 6:5-6 abstr# 6. 4. Mondy K, Haughey B, Custer P, Wippold FJ, Ritchie DJ, Mundy LM. Rhinocerebral mucormycosis in the era of lipid-based amphotericin b: case report and literature review. Pharmacotherapy 2002;22:519-26. 5. Tebas P, Henry K, Mondy K, Deeks SG, Valdez H, Cohen C, Powderly WG. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in HIV-infected patients: implications for intermittent therapeutic strategies. Journal of Infectious Diseases 2002;186:851-4. 6. Mondy K, Yarasheski K, Powderly W, Whyte M, Claxton S, Hoffman M, Tebas P. Longitudinal evolution of bone mineral density and bone markers in HIV-infected individuals. Clinical Infectious Diseases 2003;36:482-90. 7. Mondy K, Tebas P. Emerging problems of bone in HIV disease. Clinical Infectious Diseases 2003;36 (supp 2):S101-105. 8. Gerber M, Mondy K, Yarasheski KE, Dreschsler H, Claxton SA , Stoneman J, DeMarco D, Powderly WG, Tebas P. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clinical Infectious Diseases 2004;39:419-25. 9. Mondy K, Powderly W, Claxton SA, Yarasheski KE, Stoneman JS, Hoffmann ME, Tebas P. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. (Journal of AIDS, in press).
Division of Infectious Diseases
|
